CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL
Clinical trial NCT03907241 · COMPLETED
Trial details
- NCT number
- NCT03907241
- Sponsor
- Octapharma
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-03-01
- Primary completion
- 2019-09-05
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.